Obrázek na přední straně obálky pro Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study

Recenzováno

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study

Khalid Qaderdan, Maycel Ishak, Antonius A C M Heestermans, Evelyn de Vrey, J Wouter Jukema, Michiel Voskuil, Menko-Jan de Boer, Arnoud W J van't Hof, Björn E Groenemeijer, Gerrit-Jan A Vos, Paul W A Janssen, Thomas O Bergmeijer, Johannes C Kelder, Vera H M Deneer, Jurriën M ten Berg
Dual antiplatelet therapy with acetylsalicylic acid in combination with a more potent P2Y12- inhibitor (ticagrelor or prasugrel) is recommended in patients with acute coronary syndrome without ST-segment elevation (NSTE-ACS) to prevent atherothrombotic complications. The evidence on which this recommendation is based shows that ticagrelor and prasugrel reduce atherothrombotic events at the expense of an increase in bleeding events when compared with clopidogrel. However, it remains unclear whether ticagrelor or prasugrel has a better net clinical benefit in elderly patients with NSTE-ACS when compared with clopidogrel. The POPular AGE trial is designed to address the optimal antiplatelet strategy in elderly NSTE-ACS patients
Článek, 2015